Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on May 14, 2019. The filing reports financial results for the three months ended March 31, 2019, and provides an update on corporate highlights. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol "CUR."
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.01), which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It references a press release for the specific financial results and corporate updates.
Guidance, Outlook, and Risks
The company provided an update on corporate highlights as of May 14, 2019. The filing includes a standard disclaimer stating that the information furnished under Item 2.02 and the accompanying press release shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liability of such section. No specific forward-looking guidance or risk factors are detailed in the text of this form.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Press Release (Exhibit 99.01) as they are not listed in the 8-K text.
- Confirm the company name is Neuralstem, Inc., as the metadata reference to "Palisade Bio, Inc." appears to be incorrect based on the filing content.
- Review the "corporate highlights" mentioned in the press release for updates on clinical trials or product development.
- Note that the information in this filing is not deemed "filed" under Section 18 of the Exchange Act, limiting its legal liability status compared to a standard 10-Q or 10-K.